Mike Curtis

Mike Curtis, PhD, is the President and Chief Executive Officer at eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure. In this role, he is responsible for managing the development of eGenesis’ xenotransplantation programs. In 2024, Dr. Curtis landed on the TIME100 Health list for eGenesis' pioneering technology that enabled a pig kidney to be transplanted into a human.

Dr. Curtis has more than 25 years of experience in scientific research and leadership in biopharmaceutical drug development across multiple therapeutic areas. Before joining eGenesis, he served as President and Head of R&D at Cadent Therapeutics, where he oversaw R&D, regulatory and intellectual property operations. During his tenure at Cadent, the company developed a pipeline of novel therapies for the treatment of psychiatric and movement disorders leading to its acquisition by Novartis at the end of 2020.

Prior to Cadent, Dr. Curtis was responsible for product development and regulatory affairs at Catabasis Pharmaceuticals, where he led the clinical advancement of three products from discovery through first-in-human and Phase 2 studies. His first executive role was at the oncology company Infinity Pharmaceuticals, where he established and led a 30-scientist team that was responsible for all product development activities including the advancement of the lead candidates into Phase 3 clinical trials.

Dr. Curtis holds an A.Sc. in biotechnology from Cobleskill College and a B.Sc. in biochemistry from the College of Environmental Science and Forestry. He earned his doctorate in cell and molecular biology from the State University of New York Upstate Medical University.